Tamiflu dose test doubled in Asia, US
Thursday, March 29, 2007
DOCTORS in Asia and the United States will give double doses of Tamiflu to patients suffering bird flu and severe seasonal human flu from May in a trial aimed at cutting high death rates from avian flu.
People infected with the H5N1 bird flu virus are now prescribed the standard dose of Tamiflu, which is one capsule twice daily for five days. But less than half the patients survive.
"In animal studies, higher doses of Tamiflu have resulted in higher cure rates for H5N1. The death rate from H5N1 is 60 per cent, we want to see if we can solve this problem," said Tawee Chotpitayasunondh, senior medical officer at the Thai Ministry of Public Health.
Indonesia, Thailand, Vietnam and the US will participate in the clinical trial. All bird flu victims will be included in the trial; each country will pick 100 patients suffering from severe human flu. In both categories, half of the participants will be given the standard Tamiflu dosage, while the other half will be given double doses, or 150mg orally, twice daily for 10 days.
Severe human flu cases would be included because some symptoms and complications were similar to H5N1, such as pneumonia.
"We'll find out if it is safe to give double dose," Tawee said.
"We will look at clinical signs such as whether the person is feeling better. We will take secretions from the throat and lungs and check for viral load. We will check to see the progression."
For the moment, there are no commercially available vaccines against the H5N1 virus and Tamiflu is regarded as the best front-line defence against the disease if given to a patient during the early onset of symptoms.
Many nations have stockpiled the drug in the event of a pandemic. While H5N1 threatens mainly birds, experts fear it can trigger a pandemic once it learns to transmit efficiently among people. If it does, millions could die.Reuters
People infected with the H5N1 bird flu virus are now prescribed the standard dose of Tamiflu, which is one capsule twice daily for five days. But less than half the patients survive.
"In animal studies, higher doses of Tamiflu have resulted in higher cure rates for H5N1. The death rate from H5N1 is 60 per cent, we want to see if we can solve this problem," said Tawee Chotpitayasunondh, senior medical officer at the Thai Ministry of Public Health.
Indonesia, Thailand, Vietnam and the US will participate in the clinical trial. All bird flu victims will be included in the trial; each country will pick 100 patients suffering from severe human flu. In both categories, half of the participants will be given the standard Tamiflu dosage, while the other half will be given double doses, or 150mg orally, twice daily for 10 days.
Severe human flu cases would be included because some symptoms and complications were similar to H5N1, such as pneumonia.
"We'll find out if it is safe to give double dose," Tawee said.
"We will look at clinical signs such as whether the person is feeling better. We will take secretions from the throat and lungs and check for viral load. We will check to see the progression."
For the moment, there are no commercially available vaccines against the H5N1 virus and Tamiflu is regarded as the best front-line defence against the disease if given to a patient during the early onset of symptoms.
Many nations have stockpiled the drug in the event of a pandemic. While H5N1 threatens mainly birds, experts fear it can trigger a pandemic once it learns to transmit efficiently among people. If it does, millions could die.Reuters
Business Besides Oil
